Orchid Pharma's Long-Term Credit Rating Lowered to BBB+ Stable

CARE Ratings has lowered the credit rating for Orchid Pharma Ltd's long-term bank facilities by one notch, from A- to BBB+ Stable. The ₹207.50 crore in long-term debt is now rated BBB+ Stable. Ratings for ₹84.00 crore of short-term facilities were kept at A2.

Rating Details

The downgrade affects ₹207.50 crore of long-term bank facilities, now rated BBB+ Stable, down from A-. Additionally, ₹75.00 crore of facilities with mixed long-term and short-term components saw their long-term rating adjusted to BBB+ Stable, with their short-term rating reaffirmed at A2. The remaining ₹84.00 crore of purely short-term facilities were also reaffirmed at A2 by CARE Ratings. In total, CARE Ratings covers ₹366.50 crore of Orchid Pharma's facilities.

Impact of the Downgrade

A lower credit rating generally means lenders view the company as riskier. This can result in higher interest rates on future borrowing, increasing Orchid Pharma's expenses. It might also make it harder for the company to secure new loans for growth. However, the 'Stable' outlook from CARE Ratings suggests the agency anticipates the company's financial health will remain steady at this new rating level over the near to medium term.

Company Background

Orchid Pharma has previously faced significant financial difficulties. The company went through a lengthy insolvency resolution process under the Insolvency and Bankruptcy Code. It was later acquired by Dhanuka Labs, initiating a new phase focused on financial recovery. This rating update comes as Orchid Pharma continues to work on stabilizing and growing its operations following that restructuring.

What Investors Should Watch

For shareholders, higher borrowing expenses could affect the company's overall profitability. Lenders might become more cautious, potentially requiring stricter terms for any future credit. While the reaffirmed short-term rating offers some support for immediate operational needs, the company's capacity to secure significant new loans for expansion may be reduced.

Potential Risks

A point noted in the filing is that the ₹75.00 crore mixed long-term/short-term facilities do not currently include rating-related trigger clauses. However, if such clauses are introduced or activated later, it could lead to significant rating downgrades and possibly require immediate debt repayment.

Industry Context

Orchid Pharma competes in the active pharmaceutical ingredient (API) and formulation manufacturing sector, facing rivals like Laurus Labs, Divi's Laboratories, and Aarti Drugs Ltd. Like other major players, maintaining strong financial health is crucial for securing favorable borrowing terms.

Looking Ahead

Investors will want to monitor Orchid Pharma's financial results to assess its ability to manage debt and potentially improve its credit standing. Keeping an eye on any changes to its borrowing costs and terms will be important. The company's strategy for debt management and its progress toward potentially regaining higher credit ratings will also be key. Finally, any developments regarding rating-related clauses on its facilities should be watched closely.